CA2929815C - Composition & methods of screening - Google Patents

Composition & methods of screening Download PDF

Info

Publication number
CA2929815C
CA2929815C CA2929815A CA2929815A CA2929815C CA 2929815 C CA2929815 C CA 2929815C CA 2929815 A CA2929815 A CA 2929815A CA 2929815 A CA2929815 A CA 2929815A CA 2929815 C CA2929815 C CA 2929815C
Authority
CA
Canada
Prior art keywords
composition
gos
lactose
oligosaccharide
prebiotic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2929815A
Other languages
English (en)
French (fr)
Other versions
CA2929815A1 (en
Inventor
Stephen Patrick O'HARA
Robert Rastall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Optibiotix Ltd
Original Assignee
Optibiotix Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Optibiotix Ltd filed Critical Optibiotix Ltd
Priority to CA3028210A priority Critical patent/CA3028210C/en
Publication of CA2929815A1 publication Critical patent/CA2929815A1/en
Application granted granted Critical
Publication of CA2929815C publication Critical patent/CA2929815C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
    • A23L29/20—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents
    • A23L29/269—Foods or foodstuffs containing additives; Preparation or treatment thereof containing gelling or thickening agents of microbial origin, e.g. xanthan or dextran
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A23L33/25—Synthetic polymers, e.g. vinylic or acrylic polymers
    • A23L33/26—Polyol polyesters, e.g. sucrose polyesters; Synthetic sugar polymers, e.g. polydextrose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/143—Fermentum
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2400/00—Lactic or propionic acid bacteria
    • A23V2400/11—Lactobacillus
    • A23V2400/173—Reuteri
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
    • G01N2333/335—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Lactobacillus (G)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/924—Hydrolases (3) acting on glycosyl compounds (3.2)
    • G01N2333/938—Hydrolases (3) acting on glycosyl compounds (3.2) acting on beta-galactose-glycoside bonds, e.g. beta-galactosidase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Endocrinology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
CA2929815A 2013-11-05 2014-11-05 Composition & methods of screening Active CA2929815C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3028210A CA3028210C (en) 2013-11-05 2014-11-05 Use of a synbiotic composition and methods of screening for said composition

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1319539.1 2013-11-05
GBGB1319539.1A GB201319539D0 (en) 2013-11-05 2013-11-05 Composition & methods of screening
PCT/GB2014/053303 WO2015067949A1 (en) 2013-11-05 2014-11-05 Composition & methods of screening

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3028210A Division CA3028210C (en) 2013-11-05 2014-11-05 Use of a synbiotic composition and methods of screening for said composition

Publications (2)

Publication Number Publication Date
CA2929815A1 CA2929815A1 (en) 2015-05-14
CA2929815C true CA2929815C (en) 2019-02-05

Family

ID=49767702

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2929815A Active CA2929815C (en) 2013-11-05 2014-11-05 Composition & methods of screening
CA3028210A Active CA3028210C (en) 2013-11-05 2014-11-05 Use of a synbiotic composition and methods of screening for said composition

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3028210A Active CA3028210C (en) 2013-11-05 2014-11-05 Use of a synbiotic composition and methods of screening for said composition

Country Status (7)

Country Link
US (2) US9913857B2 (enExample)
EP (2) EP3892116B1 (enExample)
JP (2) JP6890972B2 (enExample)
AU (2) AU2014345344B2 (enExample)
CA (2) CA2929815C (enExample)
GB (2) GB201319539D0 (enExample)
WO (1) WO2015067949A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015013214A2 (en) 2013-07-21 2015-01-29 Whole Biome, Inc. Methods and systems for microbiome characterization, monitoring and treatment
GB201319531D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
WO2016071692A1 (en) * 2014-11-05 2016-05-12 Optibiotix Limited Prebiotic composition and its method of production
GB201319539D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening
EP4529950A3 (en) 2014-10-31 2025-08-20 Pendulum Therapeutics, Inc. Methods and compositions relating to microbial treatment
GB201509023D0 (en) * 2015-05-27 2015-07-08 Optibiotix Ltd Compositions and methods of production thereof
GB201509021D0 (en) * 2015-05-27 2015-07-08 Optibiotix Ltd Methods of screening
US20190160114A1 (en) * 2016-07-29 2019-05-30 Isothrive Llc Optimized individualized prebiotic compositions
WO2019046646A1 (en) 2017-08-30 2019-03-07 Whole Biome Inc. METHODS AND COMPOSITIONS FOR THE TREATMENT OF MICROBIOMA ASSOCIATED DISORDERS
CN113164526A (zh) 2018-07-19 2021-07-23 潘德勒姆治疗公司 用于微生物植入的方法和组合物
EP4056052A1 (en) * 2021-03-12 2022-09-14 Biogaia AB Gos pre-conditioning l. reuteri and gos in final formulation
EP4056053A1 (en) * 2021-03-12 2022-09-14 Biogaia AB Pre-conditioning of l. reuteri
KR20250035574A (ko) * 2022-07-12 2025-03-12 노보자임스 에이/에스 락토스 유발 복부 불편감의 완화 제공 방법

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69600525T2 (de) 1996-12-23 1998-12-10 Sitia-Yomo S.P.A., Mailand/Milano Lyophilisierte, lebende Bakerien enthaltende Nahrungszusammensetzung
GB0303716D0 (en) 2003-02-18 2003-03-19 Mars Uk Ltd Food product and process
MX2008015950A (es) 2006-06-13 2009-01-09 Nestec Sa Prevencion y tratamiento de la otitis media.
US20080254011A1 (en) * 2007-04-11 2008-10-16 Peter Rothschild Use of selected lactic acid bacteria for reducing atherosclerosis
US9034314B2 (en) 2008-11-03 2015-05-19 Nestec S.A. Nutritional composition comprising probiotics and improving sleep patterns
EP2216036A1 (en) 2009-02-10 2010-08-11 Nestec S.A. Lactobacillus rhamnosus NCC4007, a probiotic mixture and weight control
DK2419114T4 (da) 2009-05-01 2019-05-27 Uas Laboratories Llc Bakteriesammensætninger til profylakse og behandling af degenerative sygdomme
US20110117629A1 (en) * 2009-11-19 2011-05-19 Family Medicine Interantional Co., Ltd. Lactobacillus plantarum bb9 capable of adhering to gastrointestinal tract and cholesterol removal
CA2786710C (en) 2010-01-19 2018-10-09 Abbott Laboratories Nutritional formulas containing synbiotics
US20120263696A1 (en) 2011-04-14 2012-10-18 Stefan Roos Indirect Substrates for Microorganisms Metabolizing 1,2-Propanediol
GB201319539D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition & methods of screening

Also Published As

Publication number Publication date
GB201507664D0 (en) 2015-06-17
JP6890972B2 (ja) 2021-06-18
GB201319539D0 (en) 2013-12-18
AU2018208701A1 (en) 2018-08-16
AU2014345344B2 (en) 2018-07-05
EP3065572A1 (en) 2016-09-14
JP2019206528A (ja) 2019-12-05
JP2016537410A (ja) 2016-12-01
AU2014345344A1 (en) 2016-06-02
CA3028210C (en) 2021-11-30
CA3028210A1 (en) 2015-05-14
EP3892116A1 (en) 2021-10-13
EP3892116B1 (en) 2026-04-01
WO2015067949A1 (en) 2015-05-14
CA2929815A1 (en) 2015-05-14
EP3065572B1 (en) 2021-01-27
US9913857B2 (en) 2018-03-13
US20160263144A1 (en) 2016-09-15
US20180177817A1 (en) 2018-06-28
AU2018208701B2 (en) 2020-05-14
US10493093B2 (en) 2019-12-03

Similar Documents

Publication Publication Date Title
AU2018208701B2 (en) Composition & Methods of Screening
US12023360B2 (en) Composition and methods of screening
Kilian et al. The effects of the novel bifidogenic trisaccharide, neokestose, on the human colonic microbiota
Capela et al. Effect of cryoprotectants, prebiotics and microencapsulation on survival of probiotic organisms in yoghurt and freeze-dried yoghurt
JP6885727B2 (ja) 組成物
US11173170B2 (en) Prebiotic composition and its methods of production
US20180160713A1 (en) Methods of screening

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180511

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 10TH ANNIV.) - STANDARD

Year of fee payment: 10

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241030

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241030